X3 MICROBIOME (English)

OUR COMMITMENT WITH A HEALTHIER WORLD

X3 MicroBiome

®

THE MICROBIOTA YOUR BODY NEEDS

Xelliss Biopolis’ Bifidobacterium lactis patented strain (BLX1) is devoted to body fat reduction and cholesterol content and antioxidant activity, perfectly complementing a healthy diet and physical activity habits.

Physical activity

X3 MicroBiome is an innovative and unique concept consisting of a heat-treated Bifidobacterium lactis bacteria and a soluble fibre (Fibersol®).

Healthy diet

These two ingredients act in symbiosis and provide support for weight management.

SLIMMING

VISCERAL FAT REDUCTION

DIGESTIVE COMFORT

w w w. xe l l i s s .c o m

IMMUNE SYSTEM SUPPORT

According to the World Health Organization (WHO): “Overweight and obesity are defined as abnormal or excessive fat accumulation that presents a risk to health. A crude population measure of obesity is the body mass index (BMI), a person’s weight (in kilograms) divided by the square of his or her height (in metres). A person with a BMI of 30 or more is generally considered obese. A person with a BMI equal to or more than 25 is considered overweight. Overweight and obesity are major risk factors for a number of chronic diseases, including diabetes, cardiovascular diseases and cancer. Once considered a problem only in high income countries, overweight and obesity are now dramatically on the rise in low- and middleincome countries, particularly in urban settings.”

It is then undeniable that high cholesterol, obesity and other metabolic disordes, have a proven public interest and metabolic health component. Referring again to the World Health Organization (WHO), “an escalating global epidemic of overweight and obesity - the so called globesity – is taking over many parts of the world”.

10 facts you should know about obesity according to WHO 1. Overweight and obesity are defined as “abnormnal or excessive fat accumulation that may impair health”.

2. More than 1.9 billion adults were overweight in 2016, and 650 million obese.

3. Globally, 41 million preschool children were overweight in 2016.

4. Overweight and obesity are linked to more deaths worldwide than underweight.

5. For an individual, obesity is usually the result of imbalance between calories consumed and calories expended.

6. Supportive environment and communities are fundamental in shaping people’s choices and preventing obesity.

7. Children’s diet and physical activity habits are influenced by their surrounding environment.

8. Eating a healthy diet can help prevent obesity.

9. Regular physical activity helps maintain a healthy body.

10. Curbing the global obesity epidemic requires a population-based multisectoral, multi-disciplinary, and culturally relevant approach.

HUMAN CLINICAL TRIAL Our latest assessment of the effects of BLX1 has been a clinical trial performed with abdominally obese subjects. Results of this research have been published in the top journal on obesity and metabolic disorders, the International Journal of Obesity from Nature Publishing Group (IF = 5.16).

The clinical trial involved 135 subjects (>18 years old, mean age: 42), 126 of which finished the complete treatment after three months.

Patients had either placebo (n = 40), alive BLX1 (n = 42) or heat-killed BLX1 (n = 44). The dosage of probiotic was 1010 cfu/day (or cfu equivalent in the case of the heat-killed BLX1).

No differences in baseline characteristics were observed among intervention groups.

Both BLX1 treatments (alive and heat-killed) reduced the visceral fat area (VFA), body mass index (BMI), waist circumference (WC), waist circumference to height ratio (WHtR), and conicity index (CI).

Of particular interest is the reduction of visceral fat, which has been linked to a higher risk of stroke and other cardiovascular diseases.

The microbiome of subjects under BLX1 consumption also changed after treatment to a higher prevalence of Bifidobacterium and Akkermansia. These results support the effect of the strain on the modulation of the microbiome and energy metabolism.

Administration / jour

Placebo (n=40)

BLX1 (n=42)

BLX1 traités thermiquement (n=44)

maltodextrin

1010 cfu

1010 cellules

MAIN RESULTS • Significant reduction of waist circumference (1 – 2 cm) • Significant reduction of abdominal visceral fat (3 – 7 cm2) Changes in visceral fat area (mm2, log) 0,000 -0,005

placebo

BLX1

HT-BLX1

Changes in BMI (Kg/m2) 0,1 0

-0,004

-0,010

-0,1

-0,015

-0,2

-0,020

-0,3

0,08 BLX1

HT-BLX1

placebo -0,13

-0,023

-0,025

-0,022

Changes in Conicity index

Changes in wast circumference (cm) 0

placebo

BLX1

HT-BLX1

-0,19

0 -0,005

-0,5

-0,35

-0,4

placebo

BLX1

HT-BLX1

-0,003

-0,01 -1 -0,015 -1,5

-0,015

-0,02 -2

-1,75 -1,9

-0,025

-0,021